Sign in to view content

A Comparison of the Anatomical Efficacy of Brolucizumab Versus Aflibercept in nAMD Patients: Matched 16-Week Results From the HAWK and HARRIER Studies

Pravin U. Dugel, MD

Video
Published 2018

Related

My Practice is Worth WHAT? Equity Acquisition in the Retina World
Robert L. Avery, MD
Carl W. Baker, MD, FASRS
Michael S. Jacobson, MD
Reginald J. Sanders, MD, FASRS
Annual Meeting Talks
2018
Combination Therapy With Intravitreal Nesvacumab+Aflibercept in Diabetic Macular Edema: The Phase 2 RUBY Trial
Jeffrey S. Heier, MD
Annual Meeting Talks
2018
Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022

Category: Age-Related Macular Degeneration

See more